Moving psychopharmacological drug development to the developing world

Treating HIV in the developing world: getting ahead of the drug development curve.

At the 2006 International AIDS Conference (http://www.aids2006.org/), an impressive range of new therapeutic developments for HIV/AIDS were described. Several new drugs, and new drug classes (entry and fusion inhibitors, integrase inhibitors, and maturation antagonists) are offering great hope for more effective treatment [1]. At the same time, however, the conference also saw unrest among trea...

The changing world of drug development.

Cancer drug development is undergoing a substantial shift nowadays. The underlying drivers are multi-factorial. On the one side, drug development is performed more rationally than ever, profiting from the scientific advances in molecular biology in general and the elucidation of the various "omes" from genome to metabolome in particular. On the other side, it is based on enormous technological ...

Improving drug use for children in the developing world.

Children differ significantly from adults in the way they absorb, metabolise, and excrete drugs. These parameters also vary as children grow from neonates through to adolescence. The practical implications and challenges that this presents are well know to anyone who is involved in the medical management of sick children. The importance of paediatric medication safety and efficacy has been gain...

Antiretroviral (ARV) drug resistance in the developing world.

OBJECTIVES To describe the overall prevalence of ARV resistance in the developing world, focusing on: (1) treatment naïve populations, (2) the resistance consequences of prevention of mother to child transmission (pMTCT) drug regimens, and (3) the relationship of medication adherence to resistance. DATA SOURCES We searched PubMed(R), EMBASE, the Cochrane Controlled Clinical Trials Register Da...

Challenges of drug resistance in the developing world.